HAE Q2 Deep Dive: Plasma and Interventional Growth Drive Outperformance, Margin Outlook Steady

Blood products company Haemonetics (NYSE:HAE) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.6% year on year to $339.4 million. Its non-GAAP profit of $1.14 per share was 5.8% above analysts’ consensus estimates.

Is now the time to buy HAE? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Haemonetics delivered a Q2 performance that surpassed Wall Street’s revenue and adjusted earnings expectations, supported by consistent execution across its business lines. Management attributed the quarter’s results to strong innovation and commercial momentum, particularly in Plasma and Interventional Technologies, where new product rollouts like Persona PLUS and VASCADE MVP XL drove adoption and utilization. CEO Christopher Simon specifically highlighted, "All three of our core platforms contributed to our performance this quarter, demonstrating the breadth of our business and reinforcing the confidence in our ability to deliver sustainable long-term growth." The company’s disciplined approach to portfolio optimization and investments in sales and marketing further supported durable revenue growth.

Looking ahead, Haemonetics’ updated guidance is shaped by ongoing expansion of recurring, high-margin products and the expected acceleration of software and device rollouts such as Persona PLUS. Management remains cautious, however, about forecasting plasma collection volume growth, preferring to anchor guidance on factors within its control like market share gains and contracted rollouts. CFO James D’Arecca emphasized, “Our outlook incorporates sustained external cost pressure, which we expect to more than offset through revenue growth, favorable mix, Persona PLUS adoption, productivity and tariff recovery.” The company is focused on expanding adoption of key products, maintaining cost discipline, and pursuing targeted international growth.

Key Insights from Management’s Remarks

Management pointed to robust Plasma segment performance and resurgent Interventional Technologies as the main drivers of Q2 outperformance, with innovation and enhanced commercial execution contributing to share gains and recurring revenue.

• Plasma segment momentum: The Plasma business benefited from share gains, strong collection trends, and the initial rollout of Persona PLUS, a software upgrade that increases plasma yield for customers. Early adopters reported yield improvements exceeding 5%, and management cited ongoing adoption as a contributor to revenue durability.
• Interventional Technologies rebound: Vascular Closure devices led the recovery in Interventional Technologies, supported by the expanded indication of VASCADE MVP XL and positive clinical evidence from a large real-world study. Renewed commercial focus and improved market conditions, particularly in U.S. electrophysiology procedures, drove low double-digit growth in this franchise.
• Blood Management Technologies durability: Hemostasis Management products, especially the TEG platform and its heparinase neutralization cartridge, continued to show mid-teens growth in disposables, driven by increased utilization and market share gains. Management sees further opportunity as the segment’s upgrade cycle nears completion.
• Operating leverage and portfolio mix: The shift toward higher-margin, recurring revenue—such as consumables and software licenses—supported operating leverage, even as gross margin faced a headwind from a prior-year software benefit. Disciplined cost management and pricing actions offset external pressures like higher freight costs and inflation.
• International expansion and new launches: Growth outside North America, particularly in European plasma collections and the anticipated rollout of VASCADE MVP XL in Japan, complemented core U.S. gains. Management also highlighted ongoing investment in product launches and regulatory approvals as future growth drivers.

Drivers of Future Performance

Haemonetics’ outlook for the rest of the year centers on further adoption of innovative products, disciplined margin management, and continued international expansion.

• Persona PLUS adoption acceleration: Management expects accelerated customer upgrades to Persona PLUS, which is projected to further enhance plasma yields and productivity. The rollout pace is dictated by customer contracting, with the potential for faster adoption providing upside to revenue and margin projections.
• Margin resilience focus: The company anticipates that favorable product mix, continued pricing improvements, and operating discipline will offset external cost headwinds, including tariffs and inflation. CFO James D’Arecca noted that sequential margin expansion should occur as revenue builds through the year, with additional support from tariff refunds and internal productivity gains.
• International and new market expansion: Haemonetics aims to grow its presence in international markets, particularly as non-U.S. plasma collections now represent 20% of global volume. The company is also pursuing regulatory approvals and launches for products such as VASCADE MVP XL in Japan and PerQseal Elite in the U.S., which could create new revenue streams.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will monitor (1) the pace and breadth of Persona PLUS adoption across both U.S. and international plasma centers, (2) the progression of VASCADE MVP XL regulatory approvals and launches in key geographies like Japan, and (3) the impact of recurring revenue growth and product mix on operating margins. We will also be watching for updates on new product development and regulatory milestones that could alter Haemonetics’ addressable market.

Haemonetics currently trades at $84.98, up from $83.60 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).

High Quality Stocks for All Market Conditions

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.